OCUL

5.5704.95%
NK

Nadia K. Waheed

Chief Medical Officer

Dr. Nadia K. Waheed, M.P.H., M.D., serves as Member of Scientific Advisory Board at AAVantgarde Bio s.r.l. She serves as Chief Medical Officer of Ocular Therapeutix, Inc since June 2024. She is Director of Iolyx Therapeutics, Inc. She served as Chief Medical Adviser at Beacon Therapeutics (USA), Inc. (former name Applied Genetic Technologies Corporation) since 2024 until 2024 and served as its Chief Medical Officer since 2023 until 2024. Dr. Waheed serves as Chief Medical Officer of Gyroscope Therapeutics Holdings Limited since February 2020. She serves as Chief Medical Officer of Gyroscope Therapeutics Limited. Dr. Waheed was Director of the Boston Image Reading Center from 2015 to 2020 and serves as Consultant at the New England Eye Center at Tufts University School of Medicine in Boston since 2011. Dr. Waheed trained in Ophthalmology at the Harvard Medical School/Mass Eye and Ear Infirmary Program in Ophthalmology from 2001 to 2004, which was followed by a fellowship in retina at the Harvard Medical School/Mass Eye and Ear Infirmary in Boston. Dr. Waheed then joined the Cleveland Clinic Cole Eye Institute as faculty in 2006. This was followed by International Ophthalmology from 2009 to 2011, where she established the Retina Unit at the Shifa Hospital. Dr. Waheed received an M.D. from the Aga Khan University Medical School and a Master’s in Public Health from the Harvard School of Public Health.

Positions